



DFW

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
and
CHANGE OF CORRESPONDENCE
ADDRESS**

Application/Patent Number	10/786,380
Filing/Issue Date	February 24, 2004
First Named Inventor/Patentee	Mary Jane Cardoso
Confirmation Number	3579
Group Art Unit	1642
Examiner Name	UNKNOWN
Attorney Docket Number	2316.2009-000

Title Recombinant MVA Virus Expressing Dengue Virus Antigens and the Use Thereof in Vaccines

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ I hereby appoint the following practitioner(s): (Not to exceed 10)

OR

☒ I hereby appoint the practitioners associated with the Customer Number: **22852**

Please change the correspondence address for the above-identified application to:

☒ **Customer Number 22852**

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
901 New York Avenue, NW
Washington, D.C. 20001-4413

☐ Other _____

Please direct all telephone calls and facsimiles to:

Name Salvatore J. Arrigo Tel. No. 202-408-4160 Fax No. 202-408-4400

I am the:

☐ Applicant/Inventor.

☐ Authorized representative of the Assignee, [_____] of the entire interest. See 37 C.F.R. § 3.71. A Statement under 37 C.F.R. § 3.73(b) is enclosed.

☒ Authorized representative of the Assignee, **Universiti Malaysia Sarawak, together with Bavarian Nordic Research Institute A/S and GSF-Forschungszentrum für Umwelt und Gesundheit GmbH**, of the entire interest. A Statement under 37 C.F.R. § 3.73(b) is enclosed.

SIGNATURE of Applicant or Assignee of Record

Signature

Name & Title

DR MARY JANE CARDOSA

Date

8 FEB 2006

\\PFDesktop\pl\CDMA\MHODMA\HBSR03\IM\enpc\6022R6.1

BEST AVAILABLE COPY



Docket No. 2316.2009-000

STATEMENT UNDER 37 CFR § 3.73(b)

Applicant/Patentee: Mary Jane Cardoso, Gerd Sutter and Volker Erfle

Application No./Patent No.: 10/786,380 Filed/Issue Date: February 24, 2004

Entitled: Recombinant MVA Virus Expressing Dengue Virus Antigens and the Use Thereof in Vaccines

Universiti Malaysia Sarawak

(Name of Assignee)

a corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is

- A. ☐ the assignee of the entire right, title and interest in the patent application/patent identified above; or
- B. ☒ an assignee together with Bavarian Nordic Research Institute A/S and GSK-Forschungszentrum für Umwelt und Gesundheit GmbH of the entire right, title and interest in the patent application/patent identified above.

The right, title and interest of the above-named assignee in the patent application/patent identified above is established by virtue of:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____, Frames _____, or a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature: 

Name: MARY JANE CARDOSA

Title: DR

Date: 8 FEB 2006

BEST AVAILABLE COPY

PATENT APPLICATION
Assignment

COPY

For good and valuable consideration, the receipt of which is hereby acknowledged, I, the undersigned, inventor:

Mary Jane Cardoso

Who have created a certain invention for which I have executed, on or about the date of this assignment, an application for United States Letters Patent entitled RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS ANTIGENS, AND THE USE THEREOF IN VACCINES.


Do hereby sell, assign and transfer to Universiti Malaysia Sarawak, a corporation, having a place of business at 94300 Kota Samarahan, Sarawak, Malaysia, its successors, assigns, and legal representatives, the full and exclusive right to said invention and said application and to any and all inventions described in said invention and said application and to any and all inventions described in said application for the United States, its territorial possessions and all foreign countries, and the entire right, title and interest in and to any and all Letters Patent which may be granted therefor in the United States, its territorial possessions and all foreign countries; and in and to any and all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, and all other applications for Letters Patent relating thereto which have been or shall be filed in the United States, its territorial possession and/or any foreign countries, and all rights, together with all priority rights, under any of the international conventions, unions, agreements, act, and treaties, including all future conventions, unions, agreements, acts, and treaties;

Agree that Universiti Malaysia Sarawak, hereinafter referred to as Assignee, may apply for and receive Letters Patent for said invention and said inventions, hereinafter referred to as said invention, in its own name, in the United States, its territorial possessions, and all foreign countries; and that, when requested to carry out in good faith the intent and purpose of this assignment, at the expense of said Assignee, its successors, assigns and legal representatives, the undersigned will execute all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, execute all rightful oaths, assignments, powers of attorney and other papers, testify in any legal or quasi legal proceedings; communicate to said Assignee, its successors, assigns or legal representatives all facts known to the undersigned relating to said invention and the history thereof; and generally do everything possible which said Assignee, its successors, assigns, or legal representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said invention and for vesting title to said invention and all applications for patents on said invention in said Assignee, successors, assigns, or legal representatives; and

Covenant with said Assignee, its successors, assigns, or legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same has herein expressed is possessed by the undersigned.

IN THE TESTIMONY WHEREOF I have hereunto set my signature on the date indicated below.


Mary Jane Cardoso


Signature: Prof. Dr. Mary Jane Cardoso
Director
Institute of Health & Community Medicine
UNIVERSITI MALAYSIA SARAWAK

22/2/99

Date:


Witness:


Signature: NORRESHIKAN ABD. RAHMAN

22/2/99


Date:

Witness:


Signature: TIO PHAIK HOO

22/2/99

Date:



HAMILTON BROOK, SMITH & REYNOLDS, P.C.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
and
CHANGE OF CORRESPONDENCE
ADDRESS**

Application/Patent Number	10/786,380
Filing/Issue Date	February 24, 2004
First Named Inventor/Patentee	Mary Jane Cardoso
Confirmation Number	3579
Group Art Unit	1642
Examiner Name	UNKNOWN
Attorney Docket Number	2316.2009-000

Title Recombinant MVA Virus Expressing Dengue Virus Antigens and the Use Thereof in Vaccines

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ I hereby appoint the following practitioner(s): (Not to exceed 10)

OR

☒ I hereby appoint the practitioners associated with the Customer Number: **22852**

Please change the correspondence address for the above-identified application to:

☒ Customer Number **22852**

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
901 New York Avenue, NW
Washington, D.C. 20001-4413

☐ Other _____

Please direct all telephone calls and facsimiles to:

Name Salvatore J. Arrigo Tel. No. 202-408-4160 Fax No. 202-408-4400

I am the:

☐ Applicant/Inventor.

☐ Authorized representative of the Assignee, [_____] of the entire interest. See 37 C.F.R. § 3.71. A Statement under 37 C.F.R. § 3.73(b) is enclosed.

☒ Authorized representative of the Assignee, Bavarian Nordic Research Institute A/S, together with Universiti Malaysia Sarawak and GSF-Forschungszentrum für Umwelt und Gesundheit GmbH, of the entire interest. A Statement under 37 C.F.R. § 3.73(b) is enclosed.

SIGNATURE of Applicant or Assignee of Record

Signature Petra Pielken

Name & Title Dr. Petra Pielken, Director Patent Department

Date 01 Feb 2006

\\ppf\ppf\desktop\ODM\A\HODM\HBSR05\im\enact\602295\1

BEST AVAILABLE COPY



Docket No. 2316.2009-000

STATEMENT UNDER 37 CFR § 3.73(b)

Applicant/Patentee: Mary Jane Cardosa, Gerd Sutter and Volker Erfle

Application No./Patent No.: 10/786,380 Filed/Issued Date: February 24, 2004

Entitled: Recombinant MVA Virus Expressing Dengue Virus Antigens and the Use Thereof in Vaccines

Bavarian Nordic Research Institute A/S

(Name of Assignee)

a corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is

- A. ☐ the assignee of the entire right, title and interest in the patent application/patent identified above; or
- B. ☒ an assignee together with Universiti Malaysia Sarawak and GST-Forschungszentrum für Umwelt und Gesundheit GmbH of the entire right, title and interest in the patent application/patent identified above.

The right, title and interest of the above-named assignee in the patent application/patent identified above is established by virtue of:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____, Frames _____, or a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature: Petra Pielken

Name: Petra Pielken

Title: Director Patent Department

Date: 01 Feb 2006

BEST AVAILABLE COPY

PATENT APPLICATION
Assignment

COPY

For good and valuable consideration, the receipt of which is hereby acknowledged, I, the undersigned, inventor:

Gerd Sutter

Who have created a certain invention for which I have executed, on or about the date of this assignment, an application for United States Letters Patent entitled RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS ANTIGENS, AND THE USE THEREOF IN VACCINES.


Do hereby sell, assign and transfer to **Bavarian Nordic Research Institute A/S**, a corporation, having a place of business at Naverland 2, DK 2600-Glostrup, Denmark, its successors, assigns, and legal representatives, the full and exclusive right to said invention and said application and to any and all inventions described in said invention and said application and to any and all inventions described in said application for the United States, its territorial possessions and all foreign countries, and the entire right, title and interest in and to any and all Letters Patent which may be granted therefor in the United States, its territorial possessions and all foreign countries; and in and to any and all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, and all other applications for Letters Patent relating thereto which have been or shall be filed in the United States, its territorial possession and/or any foreign countries, and all rights, together with all priority rights, under any of the international conventions, unions, agreements, act, and treaties, including all future conventions, unions, agreements, acts, and treaties;

Agree that **Bavarian Nordic Research Institute A/S**, hereinafter referred to as Assignee, may apply for and receive Letters Patent for said invention and said inventions, hereinafter referred to as said invention, in its own name, in the United States, its territorial possessions, and all foreign countries; and that, when requested to carry out in good faith the intent and purpose of this assignment, at the expense of said Assignee, its successors, assigns and legal representatives, the undersigned will execute all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, execute all rightful oaths, assignments, powers of attorney and other papers, testify in any legal or quasi legal proceedings; communicate to said Assignee, its successors, assigns or legal representatives all facts known to the undersigned relating to said invention and the history thereof; and generally do everything possible which said Assignee, its successors, assigns, or legal representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said invention and for vesting title to said invention and all applications for patents on said invention in said Assignee, successors, assigns, or legal representatives; and

Covenant with said Assignee, its successors, assigns, or legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same has herein expressed is possessed by the undersigned.

IN THE TESTIMONY WHEREOF I have hereunto set my signature on the date indicated below.

Gerd Sutter


Signature:


2.3.99
Date:

Witness:



Signature:

02.03.99
Date:

Witness:


Signature:

2-3-99
Date:



BN 12 PCT-U.S. cont

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
and
CHANGE OF CORRESPONDENCE
ADDRESS**

Application/Patent Number	10/786,380
Filing/Issue Date	February 24, 2004
First Named Inventor/Patentee	Mary Jane Cardoso
Confirmation Number	3579
Group Art Unit	1042
Examiner Name	UNKNOWN
Attorney Docket Number	2316.2009-000

Title Recombinant MVA Virus Expressing Dengue Virus Antigens and the Use Thereof in Vaccines

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ I hereby appoint the following practitioner(s): (Not to exceed 10)

OR

☒ I hereby appoint the practitioners associated with the Customer Number: **22852**

Please change the correspondence address for the above-identified application to:

☒ Customer Number **22852**

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
901 New York Avenue, NW
Washington, D.C. 20001-4413

☐ Other _____

Please direct all telephone calls and facsimiles to:

Name Salvatore J. Arrigo Tel. No. 202-408-4160 Fax No. 202-408-4400

I am the:

☐ Applicant/Inventor.

☐ Authorized representative of the Assignee, [_____] of the entire interest. See 37 C.F.R. § 3.71. A Statement under 37 C.F.R. § 3.73(b) is enclosed.

☒ Authorized representative of the Assignee, GSF-Forschungszentrum für Umwelt und Gesundheit GmbH, together with Universiti Malaysia Sarawak and Bavarian Nordic Research Institute A/S, of the entire interest. A Statement under 37 C.F.R. § 3.73(b) is enclosed.

SIGNATURE of Applicant or Assignee of Record

Signature	<u>i.v. [Signature]</u> Feb 8, 2006	<u>i.v. [Signature]</u>
Name & Title	<u>Martin Reichel</u>	<u>Dr. Martin Dietz</u>
Date	<u>Head of Legal Department</u>	<u>Patents and Technology Transfer</u>

\\FFD\csl\top\ODM\A\HODMA\HDSR05\Manager\606299.1

BEST AVAILABLE COPY



Docket No. 2316.2009-000

STATEMENT UNDER 37 CFR § 3.73(b)

Applicant/Patentee: Mary Jane Cardoso, Gerd Suter and Volker Erlic

Application No./Patent No.: 10/786,380 Filed/Issue Date: February 24, 2004

Entitled: Recombinant MVA Virus Expressing Dengue Virus Antigens and the Use Thereof in Vaccines

GSE-Forschungszentrum für Umwelt und Gesundheit GmbH, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is

- A. ☐ the assignee of the entire right, title and interest in the patent application/patent identified above; or
- B. ☒ an assignee together with Universiti Malaysia Sarawak and Bavarian Nordic Research Institute A/S of the entire right, title and interest in the patent application/patent identified above.

The right, title and interest of the above-named assignee in the patent application/patent identified above is established by virtue of:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel , Frame , or a copy thereof is attached.

OR



- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as shown below:

1. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or a copy thereof is attached.
2. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or a copy thereof is attached.
3. From: To:
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature:  
Name: Martin Reichel Dr. Martin Dietz
Title: Head of Legal Patents and Technology
Department Transfer
Date: Feb 8, 2006

(i:\PFDesktop\ODMA\MHODMA\HDSR05\iManage\602297.1

BEST AVAILABLE COPY

PATENT APPLICATION

Assignment

For good and valuable consideration, the receipt of which is hereby acknowledged, I, the undersigned, inventor:

Volker Erfle

Who have created a certain invention for which I have executed, on or about the date of this assignment, an application for United States Letters Patent entitled **RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS ANTIGENS, AND THE USE THEREOF IN VACCINES.**

Do hereby sell, assign and transfer to **GSF - Forschungszentrum für Umwelt und Gesundheit GmbH**, a corporation, having a place of business at Ingolstädter Landstr. 1, D 85764-Neuherberg, Germany, its successors, assigns, and legal representatives, the full and exclusive right to said invention and said application and to any and all inventions described in said invention and said application and to any and all inventions described in said application for the United States, its territorial possessions and all foreign countries, and the entire right, title and interest in and to any and all Letters Patent which may be granted therefor in the United States, its territorial possessions and all foreign countries; and in and to any and all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, and all other applications for Letters Patent relating thereto which have been or shall be filed in the United States, its territorial possession and/or any foreign countries, and all rights, together with all priority rights, under any of the international conventions, unions, agreements, act, and treaties, including all future conventions, unions, agreements, acts, and treaties;

Agree that **GSF - Forschungszentrum für Umwelt und Gesundheit GmbH**, hereinafter referred to as Assignee, may apply for and receive Letters Patent for said invention and said inventions, hereinafter referred to as said invention, in its own name, in the United States, its territorial possessions, and all foreign countries; and that, when requested to carry out in good faith the intent and purpose of this assignment, at the expense of said Assignee, its successors, assigns and legal representatives, the undersigned will execute all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, execute all rightful oaths, assignments, powers of attorney and other papers, testify in any legal or quasi legal proceedings; communicate to said Assignee, its successors, assigns or legal representatives all facts known to the undersigned relating to said invention and the history thereof; and generally do everything possible which said Assignee, its successors, assigns, or legal representatives shall consider desirable for aiding in securing, maintaining and enforcing proper patent protection for said invention and for vesting title to said invention and all applications for patents on said invention in said Assignee, successors, assigns, or legal representatives; and

Covenant with said Assignee, its successors, assigns, or legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same has herein expressed is possessed by the undersigned.

IN THE TESTIMONY WHEREOF I have hereunto set my signature on the date indicated below.

Volker Erfle

Signature: *Volker Erfle*

Date: 1.3.99

Witness: *[Signature]*

Signature: *[Signature]*

Date: 02.03.99

Witness: *[Signature]*

Signature: *[Signature]*

Date: 2.3.99